The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | An overview of optimal sequencing therapy in AML
Prapti Patel, MD, University of Texas Southwestern Medical Center, Dallas, TX, gives an overview on therapy sequencing in acute myeloid leukemia (AML), and mentions the importance of the clinical data that is currently available, such as from the VIALE-A and VIALE-C trials (NCT02993523, NCT03069352). Dr Patel then mentions the importance of focusing on the biology of disease to better understand how to develop novel therapies in the future. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
Disclosures
BMS-Celgene, Agios: Membership on an entity’s Board of Directors or advisory committees; Peerview: Honoraria.
